PharmaMar announces abstract to be presented at SITC 2021

PharmaMar (MSE:PHM) has announced today that the abstract (number 464) titled “Lurbinectedin in combination with Atezolizumab for second line Extensive Stage Small Cell Lung Cancer patients” has been accepted for presentation at the upcoming Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting & Pre-Conference Programs (SITC 2021), that will take place on November 10th–14th, 2021, at the Walter E. Washington Convention Center in Washington, D.C. and virtually. Lead author, Santiago Ponce Aix, MD, Medical Oncology Specialist for Lung Cancer at HC Marbella International Hospital said: “In recent years, treatment with immunotherapy has improved survival results in small cell lung cancer, as has lurbinectedin. On this occasion, at the American Society for Immunotherapy Congress, we presented the first data on the combination of both strategies in patients with small cell lung cancer, with very good activity data and a manageable toxicity profile.”

The release as fetched from its publisher. pharmamar.com ↗